IRIS
MONDELLO, Patrizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.081
NA - Nord America 3.498
AS - Asia 2.178
SA - Sud America 741
AF - Africa 63
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.566
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.420
RU - Federazione Russa 1.787
SG - Singapore 981
BR - Brasile 634
CN - Cina 549
IE - Irlanda 531
SE - Svezia 407
PL - Polonia 315
IT - Italia 293
HK - Hong Kong 245
DE - Germania 202
VN - Vietnam 132
FI - Finlandia 125
GB - Regno Unito 120
UA - Ucraina 110
FR - Francia 92
IN - India 61
CA - Canada 35
AR - Argentina 30
MX - Messico 29
NL - Olanda 27
BD - Bangladesh 25
IQ - Iraq 24
JP - Giappone 24
BE - Belgio 20
EC - Ecuador 19
ID - Indonesia 18
UZ - Uzbekistan 17
CO - Colombia 16
TR - Turchia 16
AT - Austria 15
JO - Giordania 14
MA - Marocco 13
ZA - Sudafrica 13
ES - Italia 12
PY - Paraguay 12
PK - Pakistan 10
KE - Kenya 8
PE - Perù 8
AZ - Azerbaigian 6
CL - Cile 6
VE - Venezuela 6
BO - Bolivia 5
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
MY - Malesia 5
TN - Tunisia 5
IL - Israele 4
IR - Iran 4
LB - Libano 4
OM - Oman 4
PH - Filippine 4
SA - Arabia Saudita 4
TH - Thailandia 4
UY - Uruguay 4
AL - Albania 3
AM - Armenia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
JM - Giamaica 3
KG - Kirghizistan 3
LT - Lituania 3
NI - Nicaragua 3
NP - Nepal 3
PA - Panama 3
AO - Angola 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
KW - Kuwait 2
NG - Nigeria 2
PS - Palestinian Territory 2
RO - Romania 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CM - Camerun 1
CR - Costa Rica 1
GY - Guiana 1
HN - Honduras 1
IS - Islanda 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
MZ - Mozambico 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
Totale 10.564
Salva come PNG Salva come JPEG
Città #
Ashburn 714
Singapore 566
Dublin 531
Moscow 522
Chandler 404
Dallas 326
Warsaw 315
Hong Kong 244
Nyköping 239
Beijing 174
Jacksonville 161
Messina 147
San Jose 143
Munich 127
Dearborn 98
The Dalles 87
Los Angeles 84
Princeton 83
Medford 73
Des Moines 60
Ann Arbor 58
Lauterbourg 54
New York 54
Cambridge 52
Lancaster 52
Helsinki 51
Houston 42
São Paulo 40
Boardman 34
Wilmington 34
Redondo Beach 31
Council Bluffs 29
Woodbridge 28
Ho Chi Minh City 27
Seattle 27
Buffalo 26
Hanoi 26
Jinan 25
Rio de Janeiro 25
Dong Ket 24
Tianjin 24
San Mateo 23
Guangzhou 22
Shenyang 22
Tokyo 20
Orem 19
Brussels 18
Falls Church 18
Santa Clara 17
Montreal 16
Turku 16
Baghdad 15
Nuremberg 15
Chennai 14
Jakarta 14
Tashkent 14
Belo Horizonte 13
Brasília 13
Chicago 13
Shenzhen 13
Amman 12
Nanchang 12
Nanjing 12
Ningbo 12
Rome 12
Amsterdam 11
Milan 11
Shanghai 10
Stockholm 10
Atlanta 9
Boston 9
Brooklyn 9
Frankfurt am Main 9
Lappeenranta 9
Porto Alegre 9
Curitiba 8
Haikou 8
Pune 8
Zhengzhou 8
Campinas 7
Dhaka 7
Hangzhou 7
Hải Dương 7
Johannesburg 7
Kunming 7
London 7
Quito 7
Vienna 7
Washington 7
Aracaju 6
Auburn Hills 6
Baku 6
Columbus 6
Cuenca 6
Da Nang 6
Fairfield 6
Florianópolis 6
Goiânia 6
Hyderabad 6
Medellín 6
Totale 6.500
Salva come PNG Salva come JPEG
Nome #
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. 286
De novo mutation in SLC25A22 gene: expansion of the clinical and electroencephalographic phenotype 278
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 215
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? 215
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 209
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 208
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 201
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 186
90 Y-ibritumomab tiuxetan: A nearly forgotten opportunity 185
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 180
Emerging markers of cachexia predict survival in cancer patients. 175
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases 175
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 169
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 166
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 164
Kinase regulation of human MHC class i molecule expression on cancer cells 163
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 162
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 160
Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach 158
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 155
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. 155
Congenital heart disease in down syndrome 155
Complications of trauma patients admitted to the ICU in level i academic trauma centers in the United States 153
Thyroid function, autoimmunity and nodules in hematological malignancies 144
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 142
The heart in Anderson-Fabry disease 136
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 134
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma 133
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 133
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. 129
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. 129
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies 124
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 122
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 120
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats 117
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 116
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 113
Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice. 112
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 112
null 111
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 111
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice 108
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma 107
null 107
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model 106
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. 106
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 106
null 105
null 105
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 104
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP 103
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study 99
null 99
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 98
null 96
null 95
Effects of Apocynin, A Nadph-oxidase Inhibitor, In Contrast-induced Nephropathy 95
PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB 94
null 93
null 90
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma 89
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 86
Primary central nervous system lymphoma: Novel precision therapies 86
Emerging drugs for diffuse large B-cell lymphoma. 84
null 81
null 79
Insights into the tumor microenvironment of B cell lymphoma 78
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse 76
null 75
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis 74
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study 72
null 72
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma 69
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 68
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma 68
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 67
null 67
null 66
Pim kinases in hematological malignancies: where are we now and where are we going? 65
null 64
Questionable Validity of Cardiac Risk Score on the Basis of the NSABP B-31 Model 59
Biosimilar Erythropoietin Alpha Is Effective As Originator Erythropoietin Alpha Plus Liposomial Iron and B12 and Folates in Patients with Refractory Anemia: A Retrospective Real-Life Approach 59
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma 58
Simplified risk stratification model for patients with Waldenström macroglobulinemia 56
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy 52
null 46
R-CHOP versus R-COMP: are they really equally effective? 41
null 41
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. 36
null 35
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL 34
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 34
null 33
Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation 28
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 27
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma 25
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma 24
null 24
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity 23
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies 22
Totale 10.670
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.420
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021122 0 0 0 0 0 0 0 0 0 70 20 32
2021/2022560 3 45 19 19 30 19 20 19 8 104 66 208
2022/20231.490 136 128 85 119 91 141 14 80 628 18 37 13
2023/2024331 23 53 22 26 20 57 18 33 5 23 20 31
2024/20251.865 14 19 34 118 103 82 118 418 414 132 142 271
2025/20264.932 216 333 376 423 511 969 711 572 590 231 0 0
Totale 10.936